Research graph
References from ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine. Local targets link to admitted publications; unresolved targets remain external evidence.
The end of AIDS: HIV infection as a chronic disease.
10.1016/s0140-6736(13)61809-7 · 2013 · External reference
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
10.1016/s0140-6736(18)32462-0 · 2019 · External reference
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.
10.1093/cid/ciz1243 · 2020 · External reference
Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial.
10.1093/cid/ciac130 · 2023 · External reference
Efficacy and tollerability of INI-based 2-drug regimen in virosuppressed persons living with HIV: a systematic review and meta-analysis.
10.3947/ic.2024.0066 · 2024 · External reference
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort.
10.1111/hiv.13146 · 2021 · External reference
Interpretation and impact of real-world clinical data for the practicing clinician.
10.1007/s12325-018-0805-y · 2018 · External reference
HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review.
10.1007/s40121-021-00522-7 · 2021 · External reference
Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
10.1111/hiv.13050 · 2021 · External reference
Real-world effectiveness and tolerability of dolutegravir and lamivudine 2-drug regimen in people living with HIV: systematic literature review and meta-analysis.
10.1007/s40121-024-01103-0 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel.
10.1001/jama.2022.22246 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Probable inference, the law of succession, and statistical inference.
10.1080/01621459.1927.10502953 · 1927 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Two-drug regimens dolutegravir/lamivudine and dolutegravir/rilpivirine are effective with few discontinuations in US real-world settings: results from the TANDEM study.
10.1007/s40121-024-00961-y · 2024 · External reference
Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
10.1111/hiv.13699 · 2025 · External reference
Unresolved reference
External reference
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
10.1111/hiv.13643 · 2024 · External reference
